Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The first batches of a COVID-19 vaccine could be ready by early 2021, the company said.
 Johnson & Johnson has signed a $1 billion deal with the U.S.

Johnson & Johnson signs a COVID-19 vaccine deal with the U.S. government

Boeing

Eaton Vance Enhanced Equity Income Fund II

Home Depot

Omega Healthcare Investors

The Good Business Portfolio: Update To Guidelines March 2020

Big Pharma companies and biotechs are racing to come up with an effective treatment for the COVID-19 novel coronavirus.

Companies like Johnson & Johnson are racing to roll out Covid-19 treatments

Caterpillar

D.R. Horton

Lennar

Procter & Gamble

Royal Gold

The Federal Reserve this month cut interest rates to zero. That could be a catalyst for these 7 stocks to buy.

7 Stocks to Buy for a Dovish Federal Reserve

Gilead Sciences

A flurry of news about potential coronavirus treatments and vaccines helped shares of biopharmas Gilead Sciences, Regeneron Pharmaceuticals and Johnson & Johnson to pop Monday.
The post Covid Report: Gilead Nears Coronavirus Data In 'Weeks'; J&J Bullish On Vaccine appeared first on Investor's Business Daily.

Covid Report: Gilead Nears Coronavirus Data In 'Weeks'; J&J Bullish On Vaccine

Johnson & Johnson  said on Monday that it and the U.S. government will invest $1 billion to create enough manufacturing capacity to make more than 1 billion doses of a vaccine it is testing to stop the new coronavirus that has killed more than 35,000 people around the world.

J&J, U.S. government plan 1 billion doses of coronavirus vaccine

Abbott Labs

Novartis

Regeneron Pharmaceuticals

Sanofi

Teva Pharmaceutical

Measures currently being taken against COVID-19 are the only means of containing and suppressing the virus.

Big Pharma Advances on COVID-19

J&J's coronavirus vaccine program is moving even faster than the company anticipated.

Johnson & Johnson to Begin Testing a Coronavirus Vaccine in Humans by September

Altimmune

IMV Inc

Two coronavirus vaccine candidates are in the clinics and 42 more are in preclinical studies, according to updated data provided by the World Health Organization on March 20.

COVID-19 Vaccine Updates: J&J Identifies Lead Candidate, IMV Eyes Clinical Testing In Summer, Altimmune Partners With University Of Alabama

Johnson & Johnson  plans to start human testing of its experimental coronavirus vaccine by September and make it ready for emergency use in early 2021, the drugmaker said on Monday.

J&J to start human testing of coronavirus vaccine by September

Today's Stock Idea: Johnson & Johnson (JNJ) Potentially some of the better news we've heard on the coronavirus front over the last few weeks, J&J Monday morning announced it now has a lead vaccine candidate targeted.

Benzinga Pro's Stock To Watch For Mon., Mar. 30, 2020: Johnson & Johnson (JNJ)

Johnson & Johnson  said on Monday human testing of its experimental vaccine for the coronavirus would begin by September and that it could be available for emergency use authorization in early 2021.

Johnson & Johnson says testing of coronavirus vaccine to begin by September

Shares of Johnson & Johnson JNJ, -2.69% gained 5% in premarket trading on Monday after the company said it had identified a lead candidate in its efforts to develop a COVID-19 vaccine.

J&J has a COVID-19 vaccine candidate, Phase 1 trials to start in September

Johnson & Johnson on Monday said it has a lead vaccine candidate for COVID-19, in partnership with the U.S. Department of Health & Human Services.

Johnson & Johnson to begin clinical trials on coronavirus vaccine candidate

The health care giant has been struggling with fines related to its role in the opioid crisis and talcum powder cancer charges.

Johnson & Johnson Rebounds Below 'Reversion to the Mean'

Johnson & Johnson has steadily performed during every economic cycle.

Adding More Johnson & Johnson On The Pullback

Coca-Cola

AT&T

These extremely well-known companies are money machines for investors.

3 Brand-Name Dividend Stocks to Buy and Never Sell

Federal Realty Investment Trust

Genuine Parts

Medtronic

I believe that the Dividend Aristocrats as a group will generate solid total returns from the current level for those that buy with a long-term view

5 Undervalued Dividend Aristocrats That Have Dropped Like A Rock

Takeda Pharmaceutical

EU antitrust regulators have opened a full investigation into Johnson & Johnson's acquisition of Takeda Pharmaceutical's surgical patch product TachoSil, concerned that the deal could lead to reduced choice and higher prices for customers.

EU says Johnson & Johnson's deal for Takeda patch may harm competition

Becton, Dickinson and Co.

Ford Motor Company

Fiat Chrysler

General Motors

NuVasive

Royal Philips

ResMed

Smith & Nephew

Stryker

Tesla

Wright Medical Group

Zimmer Biomet Hlds

Some of the biggest medical device companies' stocks have dropped to attractive prices due to the current COVID-19 pandemic.

Can Medical Device Stocks Help Rebuild Your Portfolio?

What you do during this downturn could dictate your ability to generate long-term wealth.

Bear Market Investing: 3 Things to Do to Make Money

Automatic Data Processing

Air Products and Chemicals

My goal is to always provide you with the best evidence based long-term strategies for achieving their your financial goals. The latest economic news surrounding the COVID-19 pandemic is grim.

News for Johnson & Johnson Stock (JNJ)